Loading…
The study will focus on 15q13.3 CNVs with 30 subjects.
Firefly Neuroscience, Inc. and Prof. Dr. med. Christian Schaaf, Director of the Institute of Human Genetics at Heidelberg University Hospital announced on July 14, 2025 Firefly Neuroscience, Inc. announced a commercial agreement with the Institute of Human Genetics at Heidelberg University Hospital for the use of its FDA-cleared BNA™ Platform in a study on 15q13.3 CNVs.
The announcement cited 30 subjects, 15 with deletions, and 15 with duplications.
Firefly Neuroscience, Inc. Common Stock has a free float of 11,755,100 shares and 13,492,900 shares outstanding.
This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.